Charles Holley - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Director

Mr. Charles M. Holley, Jr., serves as Director of the Company. Mr. Holley has served as a director of the Company since February 1, 2017. Mr. Holley was first identified to the Governance and Nominating Committee as a potential director candidate by the Companys outside search firm. Mr. Holley is the former Executive Vice President and Chief Financial Officer for WalMart Stores, Inc., or Walmart, where he served from November 2010 to December 2015 and as Executive Vice President between January 1, 2016 and January 31, 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to November 2010. From December 2005 through December 2006, he served as Senior Vice President. Prior to that, Mr. Holley was Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in WalMart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporationrationration. He spent more than ten years with Ernst Young LLP. Mr. Holley is an Independent Senior Advisor, U.S. CFO Program, Deloitte LLP, a privatelyheld provider of audit, consulting, tax, and advisory services, since July 2016.
Age: 59  Director Since 2017      
805-447-1000  http://www.amgen.com
Holley serves on the Dean Advisory Board for the McCombs School of Business at the University of Texas at Austin and the University of Texas Presidents' Development Board.

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Arnold PinkstonBio Rad Laboratories
2017
Virgil ThompsonMallinckrodt Public Limited Com
2014
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Craig ThompsonMerck Co
2008
Laurie GlimcherBristol Myers Squibb Company
N/A
Jill SmithEndo International plc
N/A
James BloemAllergan plc
2013
Fred WeissAllergan plc
2013
Patrick OSullivanAllergan plc
2013
Michael GrobsteinBristol Myers Squibb Company
2007
Glenn TiltonAbbott Laboratories
2007
David CarlucciMallinckrodt Public Limited Com
2013
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Katherine BaickerEli Lilly and Company
2011
Thomas CechMerck Co
2009
Thomas GlocerMerck Co
2007
William YoungVertex Pharmaceuticals Incorpor
2014
Shane CookeEndo International plc
2014
Nesli BasgozAllergan plc
2014
Carlos RepresasMerck Co
2009
Edward LiddyAbbott Laboratories
2010

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.